Protocols

Bristol-Myer’s Opdivo teams up with Infinity’s last hope

Bristol-Myer’s Opdivo will team up with Infinity Pharmaceuticals’ last hope IPI-549 in a Phase I. Infinity will run the checkpoint inhibitor and PI3K-gamma inhibitor combo alongside its current trial to the test the effectiveness of the IPI-549 alone, the partnership is looking to score some points on increased potency for Opdivo. After the positive data swirled around IPI-549 at AACR, Infinity’s strategy now involves pushing the PI3k cancer drug with the checkpoint inhibitor.

Moderna CMO Tal Zaks is now on the board of directors at Adaptimmune.

Walgreen’s is trying to recoup its $140 million investment in Theranos, filing a lawsuit stating it was misled by the beleaguered blood testing company. The drugstore ended its 40-store deal to contain the Theranos testing centers last June after Federal inspections sanctioned the company, resulting in a shutdown of its blood testing services, and also banning founder Elizabeth Holmes from the industry.

 


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 35,300+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Investment Analyst
SV Health Investors Boston, MA
Research Scientist - Disease Biology
Recursion Pharmaceuticals Salt Lake City, UT
Senior Scientist - Predictive Pharmacology
Recursion Pharmaceuticals Salt Lake City, UT
Director, Translational Sciences
Cadent Therapeutics Cambridge, MA
Director of Marketing
twoXAR Mountain View, CA

Visit Endpoints Careers ->